On August 5th, Minjeong Seon, a researcher at Hana Financial Investment, announced a target price of 410,000 KRW for Hanmi Pharm, stating, "A technology transfer contract worth approximately 1 trillion KRW was signed with MSD Merck. The technology transfer amount is 870 million USD (about 1 trillion KRW), of which 10 million USD (about 12 billion KRW) is a non-refundable upfront payment. The milestone payments for clinical development, approval, and commercialization total 860 million USD, and a double-digit running royalty based on net sales will be received separately."
Over the past five days, individual investors have net purchased 103,344 shares of Hanmi Pharm, while foreigners and institutions have net purchased 31,735 shares and net sold 113,942 shares, respectively.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
